Journal ArticleDOI
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival
Fernand Labrie,André Dupont,A. Bélanger,M. Giguere,Y. Lacoursière,Jean Emond,Gerard Monfette,V. Bergeron +7 more
Reads0
Chats0
TLDR
In addition to a marked improvement in the remission rate and survival, combination therapy maintains a good quality of life, hot flashes and a decrease or loss of libido being the only side-effects.About:
This article is published in Journal of Steroid Biochemistry.The article was published on 1985-11-01. It has received 154 citations till now. The article focuses on the topics: Orchiectomy & Prostate cancer.read more
Citations
More filters
Journal ArticleDOI
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
Mario A. Eisenberger,Brent A. Blumenstein,E. David Crawford,Gary J. Miller,David G. McLeod,Patrick J. Loehrer,George Wilding,Kathy Sears,Daniel J. Culkin,Ian M. Thompson,Anton J. Bueschen,Bruce A. Lowe +11 more
TL;DR: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.
Journal ArticleDOI
DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.
TL;DR: The combination of DHEA with a fourth generation SERM, such as EM-652 (SCH 57068), a compound having pure and potent antiestrogenic activity in the mammary gland and endometrium, could provide major benefits for women at menopause (inhibition of bone loss and serum cholesterol levels) with the associated major advantages of preventing breast and uterine cancer.
Journal ArticleDOI
Prostate specific antigen only progression of prostate cancer
TL;DR: Treatment of PSA only recurrence is divided into 2 main categories of salvage local treatments and systemic therapy, and external beam radiation is the main local salvage treatment for radical prostatectomy recurrence, and cryotherapy, salvage radiotherapy versus systemic hormonal therapy are options for radiation recurrence.
Journal ArticleDOI
Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease.
Fernand Labrie,Van Luu-The,Sheng-Xiang Lin,Jacques Simard,Claude Labrie,M El-Alfy,Georges Pelletier,Alain Bélanger +7 more
TL;DR: The last and key step in the formation of all estrogens and androgens is catalyzed by members of the family of 17beta-hydroxysteroid dehydrogenases (17 beta-HSDs), which provide each cell with the means of precisely controlling the intracellular concentration of each sex steroid according to local needs.
Journal ArticleDOI
Analysis and characteristics of multiple types of human 17β-hydroxysteroid dehydrogenase
TL;DR: The different characteristics of the multiple types of human 17beta-HSD are analyzed - types 1, 3, 5 and 7 catalyze the reductive reaction, while types 2, 4 and 8 catalyzeThe oxidative reaction, and it is noteworthy that rat type 6 17 beta- HSD also catalyzes the reaction in the oxidative direction.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Extension of multiple range tests to group means with unequal numbers of replications
Abstract: In many fields of research, one is faced with the task of comparing the effects of treatments which have been replicated unequally. This happens for a number of reasons. In an experiment on animals, some may get sick and have to be removed from the experiment. In some experiments, the amount of material available for certain treatments may not be as much as for other treatments. If the experimenter has specified orthogonal contrasts that he is interested in before he runs the experiment, one can test the various treatment effects by an F-test after the treatment sum of squares has been partitioned into individual degrees of freedom for each orthogonal contrast. If the experimenter has not specified orthogonal contrasts, one is faced with the problem of deciding which treatments are significantly different. Several writers, including Duncan, Keuls, Newman, and Tukey, have developed multiple range tests to show differences among treatments that have been replicated the same number of times and when nothing was specified concerning the treatments. Duncan [1] compares the above methods and gives citations. This extension to unequal numbers of replications will be exemplified with reference to Duncan's "New Multiple Range Test," but is applicable to any of the above writers' tests; all one has to do is use their tabled ranges. In Duncan's test for an equal number of replications, the difference between any two ranked means is significant if the difference exceeds a shortest significant range. This shortest significant range is designated by R, and is obtained by multiplying the standard error of a mean, s,, by a given value, zn2, obtained from a table of significant studentized ranges which Duncan has tabled for both the 5% and 1% test. In Duncan's terminology, n2 is the degrees of freedom of the error mean square and p = 1, 2, * *, t is the number of means concerned. Consider an experiment with five treatments, A, B. C, D, and E, each replicated n times. Suppose on ranking the means from low to high one obtains
Journal ArticleDOI
The veterans administration cooperative urological research group's studies of cancer of the prostate
TL;DR: The overall recommendation at present is that patients with prostatic cancer should not be treated until their symptoms require relief, and at that time it is recommended starting treatment with 1.0 mg DES daily.
Journal ArticleDOI
Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases.
Reed M. Nesbit,William C. Baum +1 more
TL;DR: For the past eight years the physician has been confronted with problems concerning the selection of the form of endocrine modification most efficacious for the particular needs of the patient, the designation of the most opportune time to institute therapy and the choice of secondary therapy once relapse has occurred.
Journal ArticleDOI
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists
George Tolis,D. Ackman,A. Stellos,A. Mehta,Fernand Labrie,A. T. A. Fazekas,A. M. Comaru-Schally,Andrew V. Schally +7 more
TL;DR: It is concluded that superactive agonistic LH-RH analogues hold promise as therapeutic agents in patients with androgen-sensitive prostatic adenocarcinoma and may become an alternative to surgical castration and estrogen therapy for the treatment of hormone-dependent prostatic carcinoma.